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Objectives: Depression is associated with reduced cognitive function and signiﬁcant healthcare costs; however, the extent to which
these two are related remains unclear. This study compared follow-up healthcare costs for major depressive disorder patients with
and without cognitive dysfunction after antidepressant (AD) initiation. Methods: A large US health plan afﬁliated with OptumInsight
was used to identify depressed patients with a newly prescribed AD who could be surveyed to assess cognitive function. Patients with
neurological diseases associated with cognitive dysfunction were excluded. Patients were mailed a survey invitation and consent
form. Patients maintained eligibility by conﬁrming a depressive diagnosis and no excluding diagnoses. Consenting, eligible patients
were interviewed by telephone and completed 4 cognitive function tests. Patients were classiﬁed as “cognitive normal (CN)” or
“cognitive dysfunction (CD)” based on test scores relative to normative data. All-cause healthcare costs in the 3 months post-AD
initiation were calculated from pharmacy and medical claims. T-tests compared 3-month costs of CN versus CD. Gammamodels with
log link compared healthcare costs between CD and CN patients, adjusting for race, sex, age, education, employment, depression
severity, and comorbidities. Results: 13,537 patients were invited to participate in the study and 564 patients maintained eligibility
and completed the study. Patients were mostly female (80%), mean age was 41 years, 98% had a high school degree or higher, and 84%
were employed. A total of 45% (n¼255) met criteria for CD. Mean healthcare costs were $3,053 for all patients. Costs were $3,948 for the
CD group compared to $2,312 for the CN (p ¼ 0.113). In the gammamodels with costs as the outcome, CD patients had costs 1.46 times
higher than CN patients (95% CI: 1.12, 1.92)(p¼0.0059). Conclusions: In this study population, healthcare costs were signiﬁcantly higher
in patients with cognitive dysfunction compared to those without cognitive dysfunction.
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